NEWS & EVENTS
VIVOSONIC AT AAA 2026
Visit us at booth #713 to see our new 9 Series software platform in action! Experience the rapid start-up, smoother navigation and clear, uncluttered displays with an easy-to-use interface. Discover how our new Integrity version streamlines performance, improves efficiency, and delivers reliable results — for applications ranging from ABR and OAE screening and diagnostics to VEMP with EMG Monitoring. Join us for a live demo to see how Integrity can help you in your clinical practice!
Click here to learn more about our VEMP Test Type with EMG Monitoring
NEWBORN HEARING SCREENING AT A SINGLE TERTIARY CARE HOSPITAL IN THE UNITED ARAB EMIRATES
“Conclusion: The newborn screening program has run a successful journey since the beginning in the country and the current study is an example.”
STUDY: VESTIBULAR FUNCTION AND COMPLAINTS IN PATIENTS WITH UNTREATED UNILATERAL VESTIBULAR SCHWANNOMA
Conclusion: A large percentage of patients with untreated unilateral VS show unilateral vestibular dysfunction, measured by either caloric test, vHIT, or cVEMP. Objective and subjective evaluations should be viewed as complementary in elucidating the full complexity of vestibular loss in VS patients.
STUDY: AUDITORY PROCESSING AND SPEECH-SOUND DISORDERS
Poor discrimination of speech in noise imposes discrepancies between incoming auditory information and retained phonological representations, which disrupts the implicit processing mechanisms that align auditory input with phonological representations stored in memory. Speech and language pathologists can incorporate pertinent auditory processing assessment findings to identify potential language-processing challenges and formulate more effective therapeutic intervention strategies.
SEASON’S GREETINGS AND BEST WISHES FOR 2026
Please note:
Vivosonic will be closed on December 25th, 26th, 2025 and January 1st, 2026. There will be limited service on December 24th, 29th and 31st.
Regular activity begins again on January 2nd, 2026.
VIVOSONIC AT BRITISH ACADEMY OF AUDIOLOGY CONFERENCE 2025 – Telford International Centre
Join us at the upcoming BAA Annual Conference! Visit us at Booth B11 to see the unique advantages, easy-to-use features, and exceptional noise handling of the Integrity V500 System.
Learn more: https://vivosonic.com/our-technology/
VIVOSONIC AT CAA CONFERENCE 2025 – The Blue Mountains, Ontario, Canada
Come see us at the CAA Audiology Conference in October to learn about our latest features and developments. View a live demonstration!
We would be pleased to show you how easy it is to upgrade to an Integrity™ V500 System for your clinic or hospital.
For product information and sales related enquires: sales@vivosonic.com
ENHANCED AUDITORY BRAINSTEM RESPONSE DEVICE (VIVOSONIC INTEGRITY) IN YOUNG CHILDREN, IN THE CHILD’S HOME AND HOSPITAL
Creating ideal circumstances for ABR testing in children can be challenging. Skin electrodes record all physiological electrical potentials, not only responses generated by the brainstem. To optimise ABR testing, it is necessary to minimise artefacts in the obtained response and the subject is ideally asleep in a soundproof room which is free from electromagnetic interference. This study shows that “Conclusive ABR results are achievable with the Vivosonic Integrity in young children under 2 years of age in home and hospital settings, even when awake, restless, talking, eating, drinking or watching television. This eliminates the need for sleep deprivation, sedation or general anaesthesia.”
VIVOSONIC AT AAA 2025
Visit our booth (#106) at the upcoming AAA Annual Meeting on March 26-29 in New Orleans, LA
COMPARISON OF OPERATIONAL JET FUEL AND NOISE EXPOSURE FOR FLIGHT LINE PERSONNEL AT JAPANESE AND UNITED STATES AIR BASES IN JAPAN
Abstract: Flight line personnel are constantly exposed to noise and jet fuel while working on flight lines. Studies suggest that jet fuel in combination with noise affects hearing loss more than noise exposure alone. This study examined the combined effects of jet fuel and noise exposure on the hearing of flight line personnel stationed at Japan Air Self-Defense Force Air Bases (Hamamatsu, Matsushima, Hyakuri, Yokota, and Iruma) and US Air Force Air Bases (Kadena and Misawa) in Japan
SEASON’S GREETINGS AND ALL THE BEST FOR 2025!
Please note:
Vivosonic will be closed on December 25th, 26th, 2024 and January 1st, 2025. There will be limited service on December 24th, 27th and 31st.
Regular activity begins again on January 2nd, 2025.
CORRECTION FACTOR EVALUATION AND BETWEEN-SYSTEM COMPARISON OF BEHAVIORAL THRESHOLD PREDICTIONS FROM AUDITORY BRAINSTEM RESPONSE MEASURES IN INFANTS
Purpose: Auditory brainstem response (ABR) thresholds are corrected to estimate behavioral thresholds in infants. Corrections were validated, and a comparison of behavioral threshold estimates between systems was conducted to inform equipment transition and protocols in Ontario, Canada.
The audiologists obtained nHL threshold estimates from 71 infants (105 ears) using both the Biologic NavPro and the Vivosonic Integrity V500 G2 evoked potential system software.
“One difference between the Integrity and the NavPro is the use of Kalman-weighted averaging (Cone & Norrix, 2015). Kalman-weighted averaging is a statistical approach that may allow the audiologist to continue testing a patient even in the presence of high levels of background EEG or myogenic noise. It gives more weight to quiet sweeps (e.g., low noise, high signal-to-noise ratio [SNR]) and less weight to noisy sweeps (e.g., high noise, low SNR). The noisier sweeps receive a lower weighting in the overall average. Kalman weighting is used by the Integrity system, and unweighted averaging with sweep rejection is used by the NavPro system.”
“Another noted difference is that while running a single tracing, the Integrity places some of the sweeps in one buffer (A) and some in a second buffer (B) allowing essentially a “split” of a single average that has an adequate number of sweeps in each of two tracings. The protocol requires a minimum of 2,000 sweeps that are split between the two buffers. The A/B buffers are the replications for that frequency and intensity, eliminating the need to do another recording (unless the clinical scenario requires it). This removes the potential of an order bias by interleaving the sweeps composing the A/B buffers. With a minimum of 1,000 sweeps in each, the A/B results were compared to determine repeatability rather than using sequential traces like for the NavPro.”
STUDY: AUDITORY BRAINSTEM RESPONSES IN DOWN SYNDROME: EFFECTS OF STIMULUS RATE
Poster Information: This poster was presented at the American Auditory Society meeting, 2024 and discusses preliminary data and analysis as part of an ongoing study to improve hearing health and outcomes for individuals with Down Syndrome.
Methods: Data collection occurred as part of a larger study. Behavioral audiometric evaluation was performed at a previous visit. Auditory Brainstem Response testing was carried out with a Vivosonic Integrity™ V500 system.
VALGANCICLOVIR IN INFANTS WITH HEARING LOSS AND CLINICALLY INAPPARENT CONGENITAL CYTOMEGALOVIRUS INFECTION: A NONRANDOMIZED CONTROLLED TRIAL
Pui Khi Chung, MD, Fleurtje A. J. Schornagel, MD, Wim Soede, PhD, Erik W. van Zwet, PhD, Aloys C. M. Kroes, Professor, MD, PhD, Anne Marie Oudesluys-Murphy, Professor, MD, PhD, and Ann C. T. M. Vossen, PhD
J Pediatr 2024;268:113945
To assess the efficacy of valganciclovir in infants with hearing loss and clinically inapparent congenital cytomegalovirus infection (cCMV), as there is no consensus on treatment of this group.
At the follow-up age of 18–22 months, an auditory brainstem response was performed by a trained investigator during a home visit or at the study site, using a Vivosonic Integrity™ device (Vivosonic Inc., Canada).
VIVOSONIC AT AAA 2024
Visit our booth (#514) at the upcoming AAA Annual Meeting on April 17-20 in Atlanta, Georgia
SEASON’S GREETINGS AND ALL THE BEST FOR 2024!
Please note:
Vivosonic will be closed on December 22nd, 2023 until January 1st, 2024 inclusive, with limited service on December 27th and 28th.
Regular activity begins again on January 2nd, 2024.
VIVOSONIC AT BRITISH ACADEMY OF AUDIOLOGY – 19th ANNUAL CONFERENCE – November 12 – 13. 2023
Join us at the upcoming BAA Annual Conference!
Visit us at Booth A07 to see the unique advantages, easy-to-use features, and exceptional noise handling of the Integrity V500 System.
Learn more: https://vivosonic.com/our-technology/
EVALUATION OF HEARING IMPAIRMENT IN PATIENTS WITH DOWN SYNDROME
It is estimated that the prevalence of hearing loss in children with Down syndrome (DS) ranges from 38% to 82%. However, the diagnosis of hearing loss in DS is difficult, due to an impaired ability to cooperate for subjective tests. Thus, objective tests such as impedance audiometry, otoacoustic emissions, and auditory brainstem responses (ABRs) may be more appropriate. In this study objective methods without anesthesia were used to determine the amount, type, and prevalence of hearing loss in people with DS.
Read more: https://vivosonic.com/articles/
VIVOSONIC AT CAA CONFERENCE 2023 – Ottawa, Ontario, Canada
Come see us at the CAA Audiology Conference in October to learn about our latest features and developments. View a live demonstration! Vivosonic is proud to be part of the Infant Hearing Program in Ontario, which provides hearing screening for all newborns in hospital or community settings. We would be pleased to show you how easy it is to upgrade to an Integrity™ V500 System for your clinic or hospital.
For product information and sales related enquires: sales@vivosonic.com
VIVOSONIC AT EHDI 2023
Join us at the EHDI 2023 Annual Meeting, March 5 – 7, in Cincinnati, OH. Visit our Vivosonic booth (#1) and see the latest version of our Integrity™ V500 System!
RELEASE OF INTEGRITY™ VERSION 8.11
We are pleased to inform you that we have just released software ver. 8.11 for Integrity™ G2 systems. This release includes many new exciting and convenient features, such as:
• Option to purchase as a 1-channel system (Ipsilateral recording) while allowing 2-channel patient setup and automatic channel switching — upgradeable to a 2-channel system (Ipsilateral and Contralateral recording) at any time without change of hardware
• Help (?) button on all screens for quick and easy access to instructional videos and user manuals
• New RETSPL option conforming to ISO standards in addition to currently available options
• Option to preview RETSPL values on System screen
Read more: https://bit.ly/integrity-latest-features
A study of Hyperbilirubinic and normal newborns showed that Hyperbilirubinemic newborns had decreased Medial Olivocochlear (MOC) reflex activity. This may be indicative of future problems in speech discrimination and effective hearing in noisy background. Additional long cohort studies are needed to evaluate the clinical importance of MOC reflex measurements in this group.
Objective
Obstructive sleep apnea syndrome (OSAS) is a respiratory syndrome that manifests during sleep. For the auditory system to be able to function normally, the inner ear and cochlear nerve require healthy oxygen support. The purpose of this study was to assess the hearing function of patients with OSAS and to reveal the relationship between polysomnographic parameters and hearing test results.
Vivosonic’s policy is to provide support for a period of 5 years from the date of withdrawal of a product from the market. It is now over 5 years since the sale of our last new G1 system and we currently have a limited inventory of parts available to service or repair these G1 systems. We are no longer providing software updates for these G1 systems and we no longer support Windows 7. As also previously communicated, support and parts are no longer available for the XP version.
Using the Vivosonic Integrity™ V500 System, the aim of this study was to investigate the VEMP* responses in conductive hearing loss using bone conduction stimulation. The response percentage of present VEMP waves by AC stimulation was 20% (4 ears). For BC stimulation, the rate increased to 75% (15 ears).
RESEARCH ARTICLE
Early Hearing Detection and Intervention: Timely Diagnosis, Timely Management
Findlen, Ursula M.; Hounam, Gina M.; Alexy, Emily; Adunka, Oliver F.
Ear and Hearing, August 2018
This study examined how three clinical practice changes affected age at diagnosis: 1) Using Kalman-weighted signal averaging for ABR assessment, 2) Using a tone burst-prioritized protocol for assessment, and 3) Expediting the initial visit for infants.
Regarding the technology used for assessments, Kalman-weighted signal averaging ABRs may decrease the age at hearing determination for infants. Two factors decreased across the study time period: 1) The need for multiple tests to confirm diagnosis due to limited data obtained at initial evaluation and 2) difficulty testing due to limited infant sleep duration. Both of these factors can be improved by using Kalman-weighted signal averaging, which enhanced data collection efficiency when compared with conventional methods.
Click here to read full article.
Click image to view video excerpt:
Leave a Reply
You must be logged in to post a comment.